Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Hosted on MSN3h
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
McKnight's Long-Term Care News9h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The Spokesman-Review18h
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
Alaska Dispatch News19hOpinion
Opinion: We’ve accepted Wegovy and Zepbound. The next phase is harder.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).